Clinical trial
Randomised Phase 3 Trial of Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer: ENZARAD
NCT02446444 is registered in ClinicalTrials.gov with University of Sydney as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomised Phase 3 Trial of Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer: ENZARAD
- Lead sponsor
- University of Sydney
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- March 31, 2014
- Completion date
- June 30, 2026
- Enrollment
- 802 (actual)
- Sites
- 69
Conditions
As the registry lists them; a condition with its own page is linked.